Boston Scientific‘s Promus Element everolimus-eluting platinum chromium (PtCr) coronary stent system demonstrated superior safety and efficacy compared to the Promus (Xience V) everolimus-eluting coronary stent in a pivotal Platinum Workhorse trial.

The Promus Element plus stent system employs a proprietary PtCr alloy to enable visibility, less recoil, conformability and radial strength for coronary stenting, plus an advanced low-profile delivery system to facilitate precise delivery of the stent across challenging lesions.

The prospective multicentre randomised Platinum Workhorse trial enrolled 1,530 patients with up to two de novo lesions to evaluate the safety and effectiveness of the Promus element stent. The trial met its primary endpoint of 12-month two-year target lesion failure (TLF) demonstrating non-inferiority for the platinum chromium Promus Element stent compared to the cobalt chromium Promus (Xience V) stent.

Global principal investigator of the trial Gregg W. Stone said the Promus Element platinum chromium stent continues to demonstrate better safety and efficacy with low rates of cardiac death, myocardial infarction, stent thrombosis and repeat revascularisation.

"These long-term results confirm that this device is an effective option for treating patients with coronary artery disease. Of particular note, a statistically significant reduction in recurrent ischemia requiring repeat revascularization procedures was present between the first and second year with the platinum chromium stent," Stone added.

In a landmark analysis from 12 months to two years, the Promus Element stent demonstrated superior efficacy with regard to TLF and target lesion revascularisation (TLR) when compared to the Xience V stent. Boston Scientific Cardiology Division president Kevin Ballinger said with its exceptional deliverability and visibility, the Promus Element stent offers interventional cardiologists a next-generation stenting option for patients with coronary artery disease.

Image: The Promus Element stent from Boston Scientific showed efficacy in a Platinum Workhorse trial. Photo: Frank C. Müller.